JP2007529524A5 - - Google Patents

Download PDF

Info

Publication number
JP2007529524A5
JP2007529524A5 JP2007503972A JP2007503972A JP2007529524A5 JP 2007529524 A5 JP2007529524 A5 JP 2007529524A5 JP 2007503972 A JP2007503972 A JP 2007503972A JP 2007503972 A JP2007503972 A JP 2007503972A JP 2007529524 A5 JP2007529524 A5 JP 2007529524A5
Authority
JP
Japan
Prior art keywords
agent
dna
combination according
pathway
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007503972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007529524A (ja
JP5096913B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/008036 external-priority patent/WO2005089756A1/en
Publication of JP2007529524A publication Critical patent/JP2007529524A/ja
Publication of JP2007529524A5 publication Critical patent/JP2007529524A5/ja
Application granted granted Critical
Publication of JP5096913B2 publication Critical patent/JP5096913B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007503972A 2004-03-15 2005-03-14 Ｓｎｓ−５９５、及びその使用方法 Expired - Fee Related JP5096913B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55357804P 2004-03-15 2004-03-15
US60/553,578 2004-03-15
PCT/US2005/008036 WO2005089756A1 (en) 2004-03-15 2005-03-14 Sns-595 and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012036919A Division JP2012140442A (ja) 2004-03-15 2012-02-23 Ｓｎｓ−５９５、及びその使用方法

Publications (3)

Publication Number Publication Date
JP2007529524A JP2007529524A (ja) 2007-10-25
JP2007529524A5 true JP2007529524A5 (https=) 2008-07-17
JP5096913B2 JP5096913B2 (ja) 2012-12-12

Family

ID=34993432

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2007503972A Expired - Fee Related JP5096913B2 (ja) 2004-03-15 2005-03-14 Ｓｎｓ−５９５、及びその使用方法
JP2007503987A Expired - Fee Related JP5317472B2 (ja) 2004-03-15 2005-03-14 Ｓｎｓ−５９５、及びその使用方法
JP2011135675A Pending JP2011225590A (ja) 2004-03-15 2011-06-17 Ｓｎｓ−５９５、及びその使用方法
JP2012036919A Pending JP2012140442A (ja) 2004-03-15 2012-02-23 Ｓｎｓ−５９５、及びその使用方法
JP2014091125A Expired - Fee Related JP5856644B2 (ja) 2004-03-15 2014-04-25 Ｓｎｓ−５９５、及びその使用方法
JP2014180862A Expired - Fee Related JP6261477B2 (ja) 2004-03-15 2014-09-05 Ｓｎｓ−５９５、及びその使用方法
JP2015140309A Expired - Fee Related JP6352863B2 (ja) 2004-03-15 2015-07-14 Ｓｎｓ−５９５、及びその使用方法
JP2016248041A Pending JP2017095471A (ja) 2004-03-15 2016-12-21 Ｓｎｓ−５９５、及びその使用方法
JP2018038834A Pending JP2018119977A (ja) 2004-03-15 2018-03-05 Ｓｎｓ−５９５、及びその使用方法

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2007503987A Expired - Fee Related JP5317472B2 (ja) 2004-03-15 2005-03-14 Ｓｎｓ−５９５、及びその使用方法
JP2011135675A Pending JP2011225590A (ja) 2004-03-15 2011-06-17 Ｓｎｓ−５９５、及びその使用方法
JP2012036919A Pending JP2012140442A (ja) 2004-03-15 2012-02-23 Ｓｎｓ−５９５、及びその使用方法
JP2014091125A Expired - Fee Related JP5856644B2 (ja) 2004-03-15 2014-04-25 Ｓｎｓ−５９５、及びその使用方法
JP2014180862A Expired - Fee Related JP6261477B2 (ja) 2004-03-15 2014-09-05 Ｓｎｓ−５９５、及びその使用方法
JP2015140309A Expired - Fee Related JP6352863B2 (ja) 2004-03-15 2015-07-14 Ｓｎｓ−５９５、及びその使用方法
JP2016248041A Pending JP2017095471A (ja) 2004-03-15 2016-12-21 Ｓｎｓ−５９５、及びその使用方法
JP2018038834A Pending JP2018119977A (ja) 2004-03-15 2018-03-05 Ｓｎｓ−５９５、及びその使用方法

Country Status (23)

Country Link
US (12) US7989468B2 (https=)
EP (4) EP1729770B1 (https=)
JP (9) JP5096913B2 (https=)
KR (1) KR101169825B1 (https=)
CN (5) CN1997368B (https=)
AT (2) ATE493982T1 (https=)
AU (3) AU2005222607B2 (https=)
BR (1) BRPI0508700A (https=)
CA (3) CA2559652C (https=)
CY (2) CY1109741T1 (https=)
DE (2) DE602005025738D1 (https=)
DK (3) DK2295056T5 (https=)
ES (3) ES2358267T3 (https=)
HU (1) HUE027266T2 (https=)
IL (2) IL177946A (https=)
MX (2) MX349188B (https=)
NO (3) NO338058B1 (https=)
NZ (2) NZ549557A (https=)
PL (3) PL1729770T3 (https=)
PT (2) PT1729770E (https=)
SI (2) SI1725233T1 (https=)
WO (2) WO2005089757A1 (https=)
ZA (1) ZA200607248B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559652C (en) 2004-03-15 2017-02-14 Sunesis Pharmaceuticals, Inc. Methods of using sns-595 in treating cancer
WO2006034113A2 (en) 2004-09-17 2006-03-30 Cylene Pharmaceuticals, Inc. Quinolone analogs as cell proliferation inhibitors
US7652134B2 (en) 2004-09-17 2010-01-26 Cylene Pharmaceuticals, Inc. Methods for converting quinolone esters into quinolone amides
JP2009504192A (ja) * 2005-08-19 2009-02-05 サイリーン ファーマシューティカルズ インコーポレーティッド ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用
KR20080041298A (ko) * 2005-09-02 2008-05-09 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한(＋)-1,4-디히드로-7-[(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐]-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
KR20170118936A (ko) * 2005-09-02 2017-10-25 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한 (＋)-1,4-디히드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
AU2007258280B2 (en) * 2006-06-12 2013-05-02 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DK2049109T3 (en) 2006-08-02 2016-01-11 Sunesis Pharmaceuticals Inc Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
EP2209380A4 (en) * 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
EP2214662B1 (en) * 2007-10-22 2016-07-13 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
AU2014277779B2 (en) * 2007-10-22 2016-05-19 Sunesis Pharmaceuticals, Inc. METHODS OF USING (+)-1,4-DIHYDRO-7-[(3s,4s)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY
EP2249831A2 (en) * 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
KR20170090535A (ko) 2008-12-31 2017-08-07 선에시스 파마슈티컬스 인코포레이티드 (＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법
WO2010099526A1 (en) * 2009-02-27 2010-09-02 Sunesis Pharmaceuticals, Inc. Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
EP2819498B1 (en) 2012-02-27 2017-02-15 AGQ Technological Corporate S.A. Monitoring and control of soil conditions
MX371331B (es) 2012-04-24 2020-01-27 Vertex Pharma Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
ME03336B (me) 2013-03-12 2019-10-20 Vertex Pharma Inhibitori dnk-pk
US20160067182A1 (en) * 2013-04-09 2016-03-10 Merrimack Pharmaceuticals, Inc. Methods and compositions for improving outcomes of liposomal chemotherapy
US20160136173A1 (en) * 2013-07-02 2016-05-19 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - III
JP6408569B2 (ja) 2013-10-17 2018-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
KR101775356B1 (ko) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
EP3518931A4 (en) 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
WO2025033367A1 (ja) * 2023-08-04 2025-02-13 湧永製薬株式会社 抗腫瘍剤併用療法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3021A (en) * 1843-03-30 Stove with elevated ovejst
US216316A (en) * 1879-06-10 Improvement in latches
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
DK0787726T3 (da) 1994-06-14 2002-02-11 Dainippon Pharmaceutical Co Ny forbindelse, fremgangsmåde til fremstilling deraf og antitumor-middel
JP4323574B2 (ja) 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
CA2277481A1 (en) * 1997-01-13 1998-07-16 Kudos Pharmaceuticals Limited Assays, agents, therapy and diagnosis relating to modulation of cellular dna repair activity
US20020032216A1 (en) * 1997-03-21 2002-03-14 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
US6291643B1 (en) 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3
US6171857B1 (en) * 1997-10-17 2001-01-09 Brown University Research Foundatiion Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
IL124015A0 (en) * 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
JP4294121B2 (ja) 1998-06-05 2009-07-08 大日本住友製薬株式会社 ピリドンカルボン酸誘導体の製造方法およびその中間体
CA2332179C (en) * 1998-06-30 2011-06-28 Sloan-Kettering Institute For Cancer Research Uses of dna-pk
MXPA01008626A (es) * 1999-02-26 2002-04-24 Univ Johns Hopkins Inhibidor novedoso de muerte programada de celula.
US6670144B1 (en) 1999-02-26 2003-12-30 Cyclacel, Ltd. Compositions and methods for monitoring the phosphorylation of natural binding partners
US7163801B2 (en) 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
US6479541B1 (en) 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration
WO2001090404A1 (en) * 2000-05-20 2001-11-29 Cancer Research Technology Limited Drug screening systems and assays
WO2002020500A2 (en) 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
AU2001296558A1 (en) * 2000-10-03 2002-04-15 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
AU2002228772B2 (en) * 2000-11-02 2005-12-08 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors
WO2003089573A2 (en) * 2002-04-05 2003-10-30 Fishel Richard A Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof
WO2004085418A2 (en) 2003-03-24 2004-10-07 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as dna-pk inhibitors
CA2559652C (en) * 2004-03-15 2017-02-14 Sunesis Pharmaceuticals, Inc. Methods of using sns-595 in treating cancer
US8580814B2 (en) 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
KR20080041298A (ko) 2005-09-02 2008-05-09 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한(＋)-1,4-디히드로-7-[(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐]-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
AU2007258280B2 (en) * 2006-06-12 2013-05-02 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
US20100048609A1 (en) 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DK2049109T3 (en) 2006-08-02 2016-01-11 Sunesis Pharmaceuticals Inc Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
EP2214662B1 (en) 2007-10-22 2016-07-13 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
EP2249831A2 (en) 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
KR20170090535A (ko) 2008-12-31 2017-08-07 선에시스 파마슈티컬스 인코포레이티드 (＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법
WO2010099526A1 (en) 2009-02-27 2010-09-02 Sunesis Pharmaceuticals, Inc. Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
CN101631081B (zh) 2009-08-12 2011-06-08 华为技术有限公司 一种多级交换网
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer

Similar Documents

Publication Publication Date Title
JP2007529524A5 (https=)
Buzun et al. DNA topoisomerases as molecular targets for anticancer drugs
Ou et al. G‐quadruplexes: targets in anticancer drug design
ElHady et al. Advancements in phosphodiesterase 5 inhibitors: unveiling present and future perspectives
Guainazzi et al. Using synthetic DNA interstrand crosslinks to elucidate repair pathways and identify new therapeutic targets for cancer chemotherapy
Beck et al. Poly (ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3
Bhattacharya et al. Medical implications of benzimidazole derivatives as drugs designed for targeting DNA and DNA associated processes
Sissi et al. The quinolone family: from antibacterial to anticancer agents
Madaan et al. 1, 8‐Naphthyridine derivatives: A review of multiple biological activities
Abdel‐Aal et al. Towards anticancer fluoroquinolones: A review article
Mohammed et al. Current trends and future directions of fluoroquinolones
AU2011315498B2 (en) CXCR4 receptor antagonists
Peng et al. Quinazolinone azolyl ethanols: potential lead antimicrobial agents with dual action modes targeting methicillin-resistant Staphylococcus aureus DNA
Moreau et al. Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent
Driowya et al. Microwave-assisted synthesis of bioactive six-membered heterocycles and their fused analogues
ECSP055618A (es) Terapia de combinacion para enfermedades hiperproliferativas
Fantoni et al. DNA‐Targeted Metallodrugs: An Untapped Source of Artificial Gene Editing Technology
WO2005121145A3 (en) Octahydro-pyrrolo[3,4-c] derivatives and their use as antiviral compounds
Bansal et al. Topoisomerases: resistance versus sensitivity, how far we can go?
TNSN07154A1 (en) Purine derivatives for use as adenosin a-2a receptor agonists
JP2006500391A5 (https=)
Velthuisen et al. The design of 8-hydroxyquinoline tetracyclic lactams as HIV-1 integrase strand transfer inhibitors
TW200412966A (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
CN101300233A (zh) 氮杂稠合的细胞周期蛋白依赖性激酶抑制剂
Kamal et al. 1, 2, 4-Benzothiadiazine linked pyrrolo [2, 1-c][1, 4] benzodiazepine conjugates: Synthesis, DNA-binding affinity and cytotoxicity